Translational research for improving the care of familial hypercholesterolemia: The “ten countries study” and beyond

Journal of Atherosclerosis and Thrombosis

Volumn 23, Issue 8, 2016, Pages 891-900

  Watts, Gerald F ^a,b   Ding, Phillip Ya ^t   George, Peter ^c   Hagger, Martin S ^d,e,f   Hu, Miao ^g   Lin, Jie ^h   Khoo, Kah Lin ^t   Marais, A David ⁱ   Miida, Takashi ^j   Nawawi, Hapizah M ^k   Pang, Jing ^a   Park, Jeong Euy ^l   Gonzalez Santos, Lourdes B ^m   Su, Ta Chen ⁿ   Truong, Thanh Huong ^o   Santos, Raul D ^p   Soran, Handrean ^q   Yamashita, Shizuya ^r,s   Tomlinson, Brian ^g   Arikketh, Devi ^t   Ashavaid, Tester F ^t   Atiqah, Nurul ^t   Balasubramaniam, Shanthi ^t   Chan, Dick C ^t   Chang, Nien Tzu ^t   Do, Thuy Can ^t   Zhao, Dong ^t   Ellis, Katrina L ^t   Han, Ki Hoon ^t   Hardcastle, Sarah J ^t   Jannes, Cinthia E ^t   Kassim, Alicezah Mohd ^t   Ismail, Zaliha Mohd ^t   Kwok, See ^t   Lam, Carolyn Sp ^t   Lansberg, Peter J ^t   Livingston, Michael ^u   Mehta, Manjeet ^t   Muir, Lauretta ^t   Peng, Hoh Boon ^t   Pereira, Alexandre C ^t   Rahman, Thuhairah Hasrah Abdul ^t   Ramli, Anis Safura ^t   Rangarajan, Nandhini ^t   Razak, Suraya Abdul ^t   Sijbrands, Eric Jg ^t   Sullivan, David R ^t   Shyong Tai, E ^t   Tan, Hong Chan ^t   Verma, Ishwar C ^t   Wu, Xue ^t   more..

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d CURTIN UNIVERSITY   (Australia)

^e UNIVERSITY OF JYVÄSKYLÄ   (Finland)

^f GRIFFITH UNIVERSITY   (Australia)

^g CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^h CAPITAL MEDICAL UNIVERSITY   (China)

ⁱ UNIVERSITY OF CAPE TOWN   (South Africa)

^j JUNTENDO UNIVERSITY   (Japan)

^k UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^l Sungkyunkwan University School of Medicine   (South Korea)

^m PHILIPPINE GENERAL HOSPITAL   (Philippines)

ⁿ NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^o HANOI MEDICAL UNIVERSITY   (Viet Nam)

^p UNIVERSITY OF SÃO PAULO   (Brazil)

^q ST MARY S HOSPITAL   (United Kingdom)

^r OSAKA UNIVERSITY   (Japan)

^s Rinku General Medical Center   (Japan)

^t International FH Foundation ^*

^u International FH Foundation

more..

Author keywords

Asia pacific; Familial hypercholesterolaemia; Translational research

Indexed keywords

APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE 1;

AWARENESS; CARDIOVASCULAR RISK; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETIC VARIABILITY; HEALTH CARE; HUMAN; MEDICATION COMPLIANCE; MORBIDITY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT CARE; PERSONAL EXPERIENCE; PHENOTYPE; PREVALENCE; PRIMARY HEALTH CARE; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; REVIEW; TRANSLATIONAL RESEARCH; HEALTH CARE QUALITY; HYPERLIPOPROTEINEMIA TYPE II; STANDARDS;

HUMANS; HYPERLIPOPROTEINEMIA TYPE II; QUALITY OF HEALTH CARE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84980025252     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.35949     Document Type: Review

References (54)

1. Austin MA, Hutter CM, Zimmern RL and Humphries SE: Genetic causes of monogenic heterozygous familial hypercholesterolaemia: A HuGE prevalence review. Am J Epidemiol, 2004; 160: 407-420
2. Marks D, Thorogood M, Neil HAW and Humphries SE: A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis, 2003; 168: 1-14
3. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL and Motulsky AG: Hyperlipidemia in coronary heart disease 2. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest, 1973; 52: 1544-1568
4. Goldstein JL, Hobbs HH and Brown MS: The Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill Information Services Company, New York, 2001
5. Raal FJ and Santos RD: Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment. Atherosclerosis, 2012; 223: 262-268
6. Sjouke B, Kusters DM, Kindt I, Besseling J, Defesche JC, Sijbrands EJG, Roeters van Lennep JE, Stalenhoef AFH, Wiegman A, de Graaf J, Fouchier SW, Kastelein JJP and Hovingh GK: Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J, 2014; ehu058
7. Pang J, Poulter EB, Bell DA, Bates TR, Jefferson V-L, Hillis GS, Schultz CJ and Watts GF: Frequency of familial hypercholesterolemia in patients wiThearly-onset coronary artery disease admitted to a coronary care unit. J Clin Lipidol, 2015; 9: 703-708
8. Watts GF, Juniper A, van Bockxmeer F, Ademi Z, Liew D and O’Leary P: Familial hypercholesterolaemia: a review wiThemphasis on evidence for treatment, new models of care and healTheconomic evaluations. Int J Evid Based Healthc, 2012; 10: 211-221
9. Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, Bruckert E, Defesche J, Lin KK and Livingston M: Integrated Guidance on the Care of Familial Hypercholesterolaemia from the International FH Foundation. Int J Cardiol, 2014; 171: 309-325
10. Ademi Z, Watts GF, Juniper A and Liew D: A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. Int J Cardiol, 2013; 167: 2391-2396
11. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DCG, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, Kastelein JJP and Sijbrands EJG: Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. Br Med J, 2008; 337: a2423
12. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, Seed M, Humphries SE and on behalf of the Simon Broome Familial Hyperlipidaemia Register Group: Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J, 2008; 29: 2625-2633
13. Harada-Shiba M, Sugisawa T, Makino H, Abe M, Tsushima M, Yoshimasa Y, Yamashita T, Miyamoto Y, Yamamoto A, Tomoike H and Yokoyama S: Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia. J Atheroscler Thromb, 2010; 17: 667-674
14. Raal FJ, Pilcher GJ, Panz VR, van Deventer HE, Brice BC, Blom DJ and Marais AD: Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy. Circulation, 2011; 124: 2202-2207
15. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ and Defesche JC: Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease Consensus Statement of the European Atherosclerosis Society. Eur Heart J, 2013; 34: 3478-3490
16. Arai H, Ding Y-A and Yamashita S: Impact of the Integrated Guidance on the Care of Familial Hypercholesterolaemia. J Atheroscler Thromb, 2014; 21: 366-374
17. Harada-Shiba M, Arai H, Oikawa S, Ohta T, Okada T, Okamura T, Nohara A, Bujo H, Yokote K and Wakatsuki A: Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb, 2012; 19: 1043-1060
18. Watts GF, Sullivan DR, Poplawski N, van Bockxmeer F, Hamilton-Craig I, Clifton PM, O’Brien R, Bishop W, George P, Barter PJ, Bates T, Burnett JR, Coakley J, Davidson P, Emery J, Martin A, Farid W, Freeman L, Geelhoed E, Juniper A, Kidd A, Kostner K, Krass I, Livingston M, Maxwell S, O’Leary P, Owaimrin A, Redgrave TG, Reid N, Southwell L, Suthers G, Tonkin A, Towler S and Trent R: Familial hypercholesterolaemia: A model of care for Australasia. Atherosclerosis Supplements, 2011; 12: 221-263
19. Hu M, Hooper AJ, Bockxmeer FM, Watts GF, Chan JC and Tomlinson B: Management of Familial Hypercholesterolemia in Hong Kong. J Atheroscler Thromb, 2016; 23: 520-531
20. Lee SH: Characteristics and Vascular Complications of Familial Hypercholesterolemia in Korea. J Atheroscler Thromb, 2016; 23: 532-538
21. Vallejo-Vaz AJ, Kondapally Seshasai SR, Cole D, Hovingh GK, Kastelein JJP, Mata P, Raal FJ, Santos RD, Soran H, Watts GF, Abifadel M, Aguilar-Salinas CA, Akram A, Alnouri F, Alonso R, Al-Rasadi K, Banach M, Bogsrud MP, Bourbon M, Bruckert E, Car J, Corral P, Descamps O, Dieplinger H, Durst R, Freiberger T, Gaspar IM, Genest J, Harada-Shiba M, Jiang L, Kayikcioglu M, Lam CSP, Latkovskis G, Laufs U, Liberopoulos E, Nilsson L, Nordestgaard BG, O’Donoghue JM, Sahebkar A, Schunkert H, Shehab A, Stoll M, Su T-C, Susekov A, Widén E, Catapano AL and Ray KK: Familial hypercholesterolaemia: A global call to arms. Atherosclerosis, 2015; 243: 257-259
22. Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito MK, Knowles JW, McCrindle B, Raal F, Rader D, Santos RD, Lopes-Virella M, Watts GF and Wierzbicki AS: The Agenda for Familial Hypercholesterolemia-A Scientific Statement From the American Heart Association. Circulation, 2015; 132: DOI: 10.1161/CIR.0000000000000297
23. Soutar AK and Naoumova RP: Mechanisms of Disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med, 2007; 4: 214-225
24. Hooper AJ, Nguyen LT, Burnett JR, Bates TR, Bell DA, Redgrave TG, Watts GF and van Bockxmeer FM: Genetic analysis of familial hypercholesterolaemia in Western Australia. Atherosclerosis, 2012; 224: 430-434
25. Khera AV, Won H-H, Peloso GM, Lawson KS, Bartz TM, Deng X, van Leeuwen EM, Natarajan P, Emdin CA, Bick AG, Morrison AC, Brody JA, Gupta N, Nomura A, Kessler T, Duga S, Bis JC, van Duijn CM, Cupples LA, Psaty B, Rader DJ, Danesh J, Schunkert H, McPherson R, Farrall M, Watkins H, Lander E, Wilson JG, Correa A, Boerwinkle E, Merlini PA, Ardissino D, Saleheen D, Gabriel S and Kathiresan S: Diagnostic Yield of Sequencing Familial Hypercholesterolemia Genes in Patients with Severe Hypercholesterolemia. J Am Coll Cardiol, 2016; 10.1016/j.jacc.2016.1003.1520
26. Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, de Ferranti SD, Ito MK, McGowan MP, Moriarty PM, Cromwell WC, Ross JL and Ziajka PE: Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients: Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol, 2011; 5: 133-140
27. Shin DG, Han SM, Kim DI, Rhee M-Y, Lee B-K, Ahn YK, Cho BR, Woo J-T, Hur S-H, Jeong J-O, Jang Y, Lee JH and Lee S-H: Clinical features of familial hypercholesterolemia in Korea: Predictors of pathogenic mutations and coronary artery disease-A study supported by the Korean Society of Lipidology and Atherosclerosis. Atherosclerosis, 2015; 243: 53-58
28. Haralambos K, Whatley SD, Edwards R, Gingell R, Townsend D, Ashfield-Watt P, Lansberg P, Datta DBN and McDowell IFW: Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales. Atherosclerosis, 2015; 240: 190-196
29. Muir LA, George PM, Laurie AD, Reid N and Whitehead L: Preventing cardiovascular disease: a review of the effectiveness of identifying the people with familial hypercholesterolaemia in New Zealand. N Z Med J, 2010; 123: 97-102
30. Laurie AD, Scott RS and George PM: Genetic screening of patients with familial hypercholesterolaemia (FH): a New Zealand perspective. Atherosclerosis Supplements, 2004; 5: 13-15
31. Goldberg AC and Gidding SS: Knowing the Prevalence of Familial Hypercholesterolemia Matters. Circulation, 2016; 133: 1054-1057
32. Shi Z, Yuan B, Zhao D, Taylor AW, Lin J and Watts GF: Familial hypercholesterolemia in China: Prevalence and evidence of underdetection and undertreatment in a community population. Int J Cardiol, 2014; 174: 834-836
33. Watts GF, Shaw JE, Pang J, Magliano DJ, Jennings GLR and Carrington MJ: Prevalence and treatment of familial hypercholesterolemia in Australian communities. Int J Cardiol, 2015; 185: 69-71
34. de Ferranti SD, Rodday AM, Mendelson MM, Wong JB, Leslie LK and Sheldrick RC: Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation, 2016; 133: 1067-1072
35. Benn M, Watts GF, Tybjærg-Hansen A and Nordestgaard BG: Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J, 2016; 10.1093/eurheartj/ehw1028
36. Benn M, Watts GF, Tybjaerg-Hansen A and Nordestgaard BG: Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication. J Clin Endocrinol Metab, 2012; 97: 3956-3964
37. Pang J, Martin AC, Mori TA, Beilin LJ and Watts GF: Prevalence of familial hypercholesterolaemia in adolescents: potential value of universal screening ? The Journal of Pediatrics, 2016; 170: 315-316
38. De Backer G, Besseling J, Chapman J, Hovingh GK, JJP K, Ray K, Reiner Z, Wood D and De Bacquer D: Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE 4. Atherosclerosis, 2015; 241: 169-175
39. Kirke A, Watts GF and Emery J: Detecting familial hypercholesterolaemia in general practice. Aust Fam Physician, 2012; 41: 965-968
40. Qureshi N, Humphries SE, Seed M, Rowlands P, Minhas R and NICE Guideline Development Group: Identification and management of familial hypercholesterolaemia: what does it mean to primary care ? Br J Gen Pract, 2009; 59: 773-778
41. Bell DA, Garton-Smith J, Vickery A, Kirke A, Pang J, Bates TR and Watts GF: Familial Hypercholesterolaemia in Primary Care: Knowledge and Practices Among General Practitioners in Western Australia. Heart, Lung and Circulation, 2014; 23: 309-313
42. Pang J, Sullivan DR, Harada-Shiba M, Ding PY, Selvey S, Ali S and Watts GF: Significant gaps in awareness of familial hypercholesterolemia among physicians in selected Asia-Pacific countries: A pilot study. J Clin Lipidol, 2015; 9: 42-48
43. Datta BN, McDowell IF and Rees A: Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. Curr Opin Lipidol, 2010; 21: 366-371
44. National Institute for Health and Clinical Excellence and The National Collaborating Centre for Primary Care: NICE Clinical Guideline 71: Identification and management of familial hypercholesterolaemia. 2008;
45. Pedersen KMV, Humphries SE, Roughton M and Besford JS: The National Audit of the Management of Familial Hypercholesterolaemia 2010: Full report. 2010;
46. Claassen L, Henneman L, Kindt I, Marteau TM and Timmermans DRM: Perceived Risk and Representations of Cardiovascular Disease and Preventive Behaviour in People Diagnosed with Familial Hypercholesterolemia. J Health Psychol, 2010; 15: 33-43
47. Hollman G, Olsson AG and Ek A-C: Disease knowledge and adherence to treatment in patients with familial hypercholesterolemia. J Cardiovasc Nurs, 2006; 21: 103-108
48. Weiner K and Durrington PN: Patients’ understandings and experiences of familial hypercholesterolemia. Public Health Genomics, 2008; 11: 273-282
49. Muir LA, George PM and Whitehead L: Using the experiences of people with familial hypercholesterolaemia to help reduce the risk of cardiovascular disease: a qualitative systematic review. J Adv Nurs, 2012; 68: 1920-1932
50. Hardcastle SJ, Legge E, Laundy CS, Egan SJ, French R, Watts GF and Hagger MS: Patients’ Perceptions and Experiences of Familial Hypercholesterolemia, Cascade Genetic Screening and Treatment. International Journal of Behavioral Medicine, 2015; 22: 92-100
51. Hagger MS, Hardcastle SJ, Hingley C, Strickland E, Pang J and Watts GF: Predicting Self-Management Behaviors in Familial Hypercholesterolemia Using an Integrated Theoretical Model: the Impact of Beliefs About Illnesses and Beliefs About Behaviors. International Journal of Behavioral Medicine, 2016; 23: 282-294
52. Ramaswami U, Cooper J and Humphries SE: The UK Paediatric Familial Hypercholesterolaemia Register: preliminary data. Arch Dis Child, 2016; 10.1136/archdischild-2015-308570
53. Screening Project for Familial Hypercholesterolemia in Central, Southern and Eastern Europe. 2015; http://screenprofh.com/
54. Pang J, Lansberg PJ and Watts GF: International Developments in the Care of Familial Hypercholesterolemia: Where Now and Where to Next ? J Atheroscler Thromb, 2016; 23: 505-519